| Compound Information | SONAR Target prediction |
| Name: | ORLISTAT |
| Unique Identifier: | SPE01504300 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 442.314 g/mol |
| X log p: | 1.777 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 69.67 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 6 |
| Rotatable Bond Count: | 24 |
| Canonical Smiles: | CCCCCCCCCCCC(CC1OC(=O)C1CCCCCC)OC(=O)C(CC(C)C)NC=O |
| Source: | synthetic |
| Therapeutics: | reversible lipase inhibitor, antiobesity |
| Generic_name: | Orlistat |
| Chemical_iupac_name: | 1-(3-hexyl-4-oxo-oxetan-2-yl)tridecan-2-yl 2-formylamino-4-methyl-pentanoate |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA450714 |
| Drugbank_id: | APRD00255 |
| H2o_solubility: | Practically insoluble |
| Logp: | 8.533 |
| Isoelectric_point: | No pKa within the physiological pH range. |
| Cas_registry_number: | 96829-58-2 |
| Drug_category: | Anti-Obesity Agents; Enzyme Inhibitors; ATC:A08AB01 |
| Indication: | For obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Also used to reduce the risk for weight regain after prior weight loss. |
| Pharmacology: | Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats. At the recommended therapeutic dose of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%. It works by inhibiting pancreatic lipase, an enzyme that breaks down fat in the intestine. Without this enzyme, fat from the diet is excreted undigested, and not absorbed by the body. Because some vitamins are fat soluble, the effect of orlistat is to reduce their body absorption. Therefore the drug should only be taken in conjuction with fatty meals, and a multivitamin tablet containing these vitamins (D E K and beta-carotene) should be taken once a day, at least 2 hours before or after taking the drug. In the March 15, 2004 issue of Cancer Research,[1] Steven J. Kridel et al. state that orlistat may also inhibit growth of prostate cancer, and in theory may be useful in treating other cancers, by interfering with the metabolism of fats. |
| Mechanism_of_action: | Orlistat is a reversible inhibitor of lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control. |
| Organisms_affected: | Humans and other mammals |
| Found: 192 nonactive as graph: single | with analogs | [1] << Back 191 192 Next >> [192] |
| Species: | 4932 |
| Condition: | YPT6 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.4164±0.0168999 |
| Normalized OD Score: sc h | 1.0879±0.0047164 |
| Z-Score: | 0.7316±0.0540672 |
| p-Value: | 0.464728 |
| Z-Factor: | -0.887481 |
| Fitness Defect: | 0.7663 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 5 |
| 4599 | 1-(3-hexyl-4-oxo-oxetan-2-yl)tridecan-2-yl 2-formamido-4-methyl-pentanoate |
| 3034010 | [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methyl-pentanoate |
| 5284600 | [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]tridecan-2-yl] 2-formamido-4-methyl-pentanoate |
| 6710691 | [(2S)-1-[(2R,3S)-3-hexyl-4-oxo-oxetan-2-yl]tridecan-2-yl] (2R)-2-formamido-4-methyl-pentanoate |
| 15973425 | [(2S)-1-[(2S,3S)-3-(5-methylhexyl)-4-oxo-oxetan-2-yl]tridecan-2-yl] (2R)-2-formamido-4-methyl-pentanoate |
| internal high similarity DBLink | Rows returned: 0 |
| active | Cluster 4053 | Additional Members: 2 | Rows returned: 0 |
Service provided by the
Mike Tyers Laboratory